WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ: ARQL) today announced that eleven abstracts submitted by the Company were presented at the 2007 Annual Meeting of the American Association for Cancer Research (AACR), April 14-18, 2007 in Los Angeles. The AACR abstracts are based on pre-clinical studies that provide a rationale for the Company’s approaches to cancer therapy as embodied in its c-Met inhibition and DNA damage response/checkpoint activation platforms. They add significantly to the database of knowledge related to the Company’s clinical-stage products, ARQ 197 and ARQ 501, and represent a broad scope of findings from in vitro (cell line) and in vivo (animal) experiments. Summaries of these studies are presented below.
